IBM and Pfizer File Prospectus for IoT-Based Parkinson’s Patient-Physician Communication System

Recently, IBM and Pfizer have launched an unprecedented collaboration in the field of IoT-enabled healthcare. The two companies aim to develop a remote control system to facilitate better communication between physicians and Parkinson’s disease patients. This pilot project is based on a sensor system, mobile devices, and machines that provide physicians and researchers with 24-hour real-time patient data.

Parkinson’s Disease Requires Enhanced Disease Progression Monitoring and Communication: IBM and Pfizer Collaborate Using Big Data

According to the World Health Organization, neurological disorders include Parkinson’s disease, Alzheimer’s disease, stroke, and epilepsy, affecting one billion families worldwide. Each year, deaths attributable to these conditions account for 12% of global mortality. Many brain, spinal, and neurological diseases are significantly influenced by disease progression; patients’ physical conditions tend to deteriorate over time, potentially leading to uncontrollable complications that impair cognitive function or cause gradual physical decline. These outcomes substantially impact patients’ quality of life.

According to data from the Parkinson’s Foundation, approximately 60,000 Americans are diagnosed with Parkinson’s disease each year, and 7 out of every 10 million people worldwide are affected by the condition. It is reported that in early March this year, IBM held a forum themed “Embracing the Cognitive Era: IBM Partners with You to Win the Future with Intelligence.” At the event, IBM showcased its collaborative achievements with Pfizer China in the healthcare sector. IBM China and Pfizer, in partnership with medical institutions, leveraged big data and cognitive analytics to develop a chronic disease risk prediction model tailored to the characteristics of the Chinese population. This model efficiently identifies key risk factors and accelerates the pace of scientific discovery.

IBM and Pfizer have announced that the project will be rapidly advanced to the initial clinical testing phase. Furthermore, the two companies will engage patients, advocacy organizations, physicians, and neurology experts to provide guidance on the technologies, medical devices, and data processing involved in the project. The team will develop appropriate protocols to offer clear and accessible instructions for patients using the devices.

The project can help physicians develop more optimized diagnosis and treatment plans, thereby advancing the discovery of new approaches to the diagnosis and management of Parkinson’s disease.

The purpose of this collaboration between the two companies is to enable physicians to better understand the clinical status and medication feedback of patients with Parkinson’s disease, thereby assisting them in making treatment decisions and designing diagnostic and therapeutic plans. Meanwhile, the project also advances the development of new approaches to the diagnosis and treatment of Parkinson’s disease.

Parkinson’s disease particularly requires physicians to continuously adjust medication based on the patient’s disease course and self-reported feedback. The company aims to make a comprehensive assessment of patients’ conditions by analyzing multiple physiological factors, including muscle function, severity of movement disorders, cognitive status, sleep patterns, and activities of daily living. By observing these data, physicians can understand the impact of medications on the disease progression and adjust treatment plans as needed. The data generated by the system provides clinical cases for researchers, who can leverage these cases to develop improved medical strategies for the future.

“With the development of digital healthcare informatics, it has become increasingly difficult to collect physiological data in real time to support disease diagnosis and treatment,” said Arvind Krishna, Senior Vice President at IBM Research. “We are working to establish a system for collecting patient condition data that does not impose additional burdens on patients, while providing physicians and researchers with real-time, objective information. We believe this information will fundamentally transform how physicians guide and treat their patients.”

GuanOn Parkinson's Disease

Parkinson's disease is a common neurodegenerative disorder that predominantly affects the elderly, with an average age of onset around 60 years. Young-onset Parkinson's disease, occurring before the age of 40, is relatively rare. Statistics indicate that there are approximately 4.5 million Parkinson's patients worldwide, with nearly half residing in China. Currently, China has 2.2 million individuals living with Parkinson's disease. In China, over 1% of the population aged 60 and above suffers from Parkinson's disease; this prevalence rises to approximately 1.7% among those aged 65 and older, and reaches 3%–5% in individuals over 70. As the "third major killer" of middle-aged and elderly people, following cancer and cardiovascular and cerebrovascular diseases, Parkinson's disease sees nearly 100,000 new cases annually.

WHO experts predict that the number of Parkinson’s disease patients in China will reach 5 million by 2030. Currently, Parkinson’s disease is trending toward younger age groups, with patients diagnosed with “juvenile-onset Parkinson’s disease” accounting for 10% of the total patient population.

The primary pathological change in Parkinson’s disease is the degeneration and death of dopaminergic neurons in the substantia nigra of the midbrain, which leads to a significant reduction in dopamine (DA) levels in the striatum, thereby causing the disease. The exact etiology underlying this pathological change remains unclear; however, genetic factors, environmental factors, aging, and oxidative stress are all believed to contribute to the degeneration and death of dopaminergic neurons in PD.

Since 1997, the European Parkinson’s Disease Association has designated April 11 each year as “World Parkinson’s Disease Day” to encourage patients, their families, and healthcare professionals to work together not only to raise awareness of Parkinson’s disease but also to heighten public attention.

Author: Deng Xueyuan | Editor: Li Simeng